Development and Validation of a Screening Assay for the Evaluation of Putative Neuroprotective Agents in the Treatment of Parkinson’s Disease
Authors:
- 2 April 2010
- journal article
- research article
- Published by Springer Nature in Neurotoxicity Research
- Vol. 19 (4) , 519-526
Abstract
Following initial diagnosis of Parkinson’s disease, if it were possible to prescribe a treatment that could halt or prevent further neurodegeneration, disease progression could be prevented. The aim of this study was to generate a quick and reliable assay for assessing putative neuroprotective agents for parkinsonian patients. Abnormalities in mitochondria, proteasome and lysosome function, as well as oxidative stress cause cell death in Parkinson’s disease. Thus, we exposed neuroblastoma (SH-SY5Y) cells to EC50 of toxins that mimic these cell death mechanisms (dopamine to induce oxidative stress; naphthazarin to inhibit lysosome function; proteasome inhibitor N-carbobenzyloxy-Ile-Glu(O-t-butyl)-Ala-leucinal (PSI) to inhibit the UPS (ubiquitin proteasome system) and rotenone to inhibit mitochondria function) in the presence of five compounds previously chosen as neuroprotective agents, and assessed cell viability. Coenzyme Q10 (117 μM) significantly protected against four toxins, dopamine: 16.3 ± 3.3%; naphthazarin: 10.8 ± 1.1%; PSI: 16.2 ± 2.9%; rotenone: 53.2 ± 4.2%; whereas caffeine (140 μM), creatine (25 mM), nicotine (1 μM) and deprenyl (10 μM) provided protection against some, but not all toxins. Interestingly, coenzyme Q10 is the only compound out of the five that showed neuroprotective potential in clinical trials. Thus, there is a direct correlation between the success of disease modifying agents in the clinic and their ability to protect against multiple cell death mechanisms in this assay. We propose that exposure of SH-SY5Y cells to different toxins that recapitulate cell death mechanisms in Parkinson’s disease serves as a rapid and reliable method to test neuroprotective agents that may succeed in clinical trials.Keywords
This publication has 44 references indexed in Scilit:
- Paraquat induces oxidative stress, neuronal loss in substantia nigra region and Parkinsonism in adult rats: Neuroprotection and amelioration of symptoms by water-soluble formulation of Coenzyme Q10BMC Neuroscience, 2009
- Creatine supplementation in Parkinson disease: A placebo-controlled randomized pilot trialNeurology, 2006
- Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPaseNature Genetics, 2006
- Proteolysis: from the lysosome to ubiquitin and the proteasomeNature Reviews Molecular Cell Biology, 2005
- Recent developments in the pharmacological treatment of Parkinson’s diseaseExpert Opinion on Investigational Drugs, 2003
- From chemical to drug: neurodegeneration drug screening and the ethics of clinical trialsNature Neuroscience, 2002
- Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutaminesNature Neuroscience, 2002
- Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicityBrain Research, 2000
- Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in miceNaunyn-Schmiedeberg's Archives of Pharmacology, 1999
- DOPAMINE (3-HYDROXYTYRAMINE) AND BRAIN FUNCTIONPharmacological Reviews, 1966